I couldn't disagree more about the name change Gassey. The...

I couldn't disagree more about the name change Gassey. The "Antisense Therapeutics" name franchise is well known and respected by pharma, biotechs, instos, analysts, HNW investors, clinicians, and DMD patient advocacy groups. If the name is changed to Percheron, all of these groups will have to be re-educated, and that is not as easy as you might think. 20 plus years nurturing these relationships will be undone if the name is changed now. ANP would surely fall completely off the radar of some of them. These groups will be absolutely crucial when Filippis seeks a commercial deal after the DMD trial results are in. Percheron will mean nothing to most of them and it is complete fantasy to think that a potential commercial partner or collaborator will attribute any value at all to a deal just because the company is named after a strong horse; if indeed they even know that Percheron is a horse. Where is the independent business analysis that demonstrates a compelling case for name change to Percheron. Or indeed ANY benefit at all. Management should be focussing 100% on getting the DMD trial done on time and on budget.